폐암 환자의 항암화학요법 유발성 호중구감소증 관련요인
Factors Related to Chemotherapy-Induced Neutropenia in Lung Cancer Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to identify the incidence of chemotherapy-induced neutropenia (CIN) and its associated factors in patients with lung cancer. Methods: Data from the electronic medical records of 181 patients with lung cancer who received their first cycle of chemotherapy at P University Hospital, City B, between January 1 and December 31, 2019, were analyzed. The collected data included general and clinical characteristics, treatment-related factors, hematologic parameters, and CIN-related variables. Statistical analysis was performed using SPSS software version 23.0, employing descriptive statistics, the x2 test, Fisher’s exact test, and logistic regression. Results: CIN occurred in 22.7% of the participants, of whom 7.3% developed febrile neutropenia (FN). The risk of CIN was 3.13 times higher in patients with mildly decreased glomerular filtration rate (GFR, 60-89 mL/min) than in those with normal GFR (≥90 mL/min, p=.007), and 2.69 times higher in patients treated with an etoposide and platinum regimen than in those who received other regimens (p=.019). The logistic regression model indicated a good fit (x2=2.53, p=.772), explaining 14.1% of the variance (Nagelkerke R2=.14). Conclusion: The risk of CIN was elevated among patients with mildly decreased GFR and those receiving etoposide along with platinum chemotherapy. Therefore, infection prevention education and close monitoring for signs of infection are essential for high-risk patients with impaired renal function to enable early detection and effective management of FN during the CIN period.
Abstract
Purpose: This study aimed to identify the incidence of chemotherapy-induced neutropenia (CIN) and its associated factors in patients with lung cancer. Methods: Data from the electronic medical records of 181 patients with lung cancer who received their first cycle of chemotherapy at P University Hospital, City B, between January 1 and December 31, 2019, were analyzed. The collected data included general and clinical characteristics, treatment-related factors, hematologic parameters, and CIN-related variables. Statistical analysis was performed using SPSS software version 23.0, employing descriptive statistics, the x2 test, Fisher’s exact test, and logistic regression. Results: CIN occurred in 22.7% of the participants, of whom 7.3% developed febrile neutropenia (FN). The risk of CIN was 3.13 times higher in patients with mildly decreased glomerular filtration rate (GFR, 60-89 mL/min) than in those with normal GFR (≥90 mL/min, p=.007), and 2.69 times higher in patients treated with an etoposide and platinum regimen than in those who received other regimens (p=.019). The logistic regression model indicated a good fit (x2=2.53, p=.772), explaining 14.1% of the variance (Nagelkerke R2=.14). Conclusion: The risk of CIN was elevated among patients with mildly decreased GFR and those receiving etoposide along with platinum chemotherapy. Therefore, infection prevention education and close monitoring for signs of infection are essential for high-risk patients with impaired renal function to enable early detection and effective management of FN during the CIN period.